New hope for aggressive ovarian cancer: targeted drug combo enters trial
Disease control
Recruiting now
This study tests a new drug combination for people with a specific, high-risk type of ovarian cancer that has not yet been treated. The treatment includes a targeted drug (disitamab vedotin) plus standard chemotherapy and a blood-vessel blocker (bevacizumab). After initial treatm…
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated May 17, 2026 08:01 UTC